Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
about
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsGuidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsSoluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical RelevanceRole of mesenchymal cells in the natural history of ovarian cancer: a reviewEGFR/HER-targeted therapeutics in ovarian cancerOvarian cancer biomarker discovery based on genomic approachesEGF receptor trafficking: consequences for signaling and cancerNew perspectives on targeted therapy in ovarian cancerActivation of Rac1-PI3K/Akt is required for epidermal growth factor-induced PAK1 activation and cell migration in MDA-MB-231 breast cancer cells.EGFR soluble isoforms and their transcripts are expressed in meningiomas.Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.Targeting the EGF receptor for ovarian cancer therapy.Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid.Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasionEpidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagenAndrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cellsTrastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cellsSerum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.Investigational agents in development for the treatment of ovarian cancerHomeobox A7 increases cell proliferation by up-regulation of epidermal growth factor receptor expression in human granulosa cellsEGFR isoforms and gene regulation in human endometrial cancer cellsHigh incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckTransforming growth factor alpha (TGFα) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways.Primary trastuzumab resistance: new tricks for an old drug.Protein biomarkers of ovarian cancer: the forest and the treesTime-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodiesLayered signaling regulatory networks analysis of gene expression involved in malignant tumorigenesis of non-resolving ulcerative colitis via integration of cross-study microarray profiles.The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity.Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling.Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.Effect of epidermal growth factor on follicle-stimulating hormone-induced proliferation of granulosa cells from chicken prehierarchical folliclesFractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model
P2860
Q24302462-CEDBD5BF-497C-45B6-AAAD-54C9115BB440Q26738643-C3935B83-20B6-4729-A9F1-156149B60A16Q26750970-DA334664-B49B-45DF-A401-0E8EE4377A0FQ26823555-45F7BCFD-22BD-4E9D-AD1E-79F3E3991F59Q26863231-55C98643-B233-429B-9916-C80C73A4F0FAQ27013687-9541CF91-4DF3-4576-9660-411C73D4A7F7Q27021340-CCFD0CD8-8A9C-4236-8388-864480471D81Q28082524-99C09E94-113F-4921-A084-9AD5E9A3A18EQ30420138-B150B89B-8220-40FE-B7AF-4F0190A363AEQ31062214-88BA4A0B-D34C-4A5C-BEA3-A66B20B28942Q33412801-C6D2C42C-F025-4C4B-82FC-9B5342EDFDF1Q33570526-B35AC932-ABF3-44E0-A277-8DACE7F30B91Q33634483-B594A820-850A-4BB5-AEA5-74B31C01298FQ33642087-1B32B920-79B3-4342-86D3-A51B8310643EQ33744931-1869F670-2974-4BB6-A0D5-5803A07805FFQ33772886-386F2915-16E1-4285-ADE4-B1356C9B082EQ33816185-58351477-8DDD-4DD4-9231-E6F761E84D5AQ33829859-E992732B-8898-499D-877C-D174789C8A5BQ33862961-8784438D-4CA5-4BC6-84CD-3E9C0CA76AE7Q33920800-B6CBA01F-876D-4F1B-8E43-6B37BD62E854Q33998155-703218EC-D6E4-4383-A3CC-F64CE6883B90Q34008570-578EB60A-653C-4112-80A4-777782EC0B1EQ34128962-4B77ACE6-85D5-467B-AA7B-6CCD4A96D3C7Q34159125-858E7E06-475F-4BED-94BA-17D2F49D4AA3Q34478979-E46FCA78-0A3E-48A2-8A2A-0B0269BC0C00Q34610251-929D5C53-170E-470C-9EBF-8F80D5A6F85AQ34634143-14B62596-6F75-47EE-89A0-2EE58E62DC72Q34719632-2D2E44AB-B3C3-46D3-BA75-2491D98B153BQ34794766-F60B90B5-BCC0-4D55-BBFF-01A5CD762DAFQ34806737-8F247176-5E46-4AAE-9831-2F9F71C84B6AQ34878868-E168E6E1-2053-4C3B-AA37-A104E4B8355FQ34887667-33D311E0-344F-41D5-A777-47E196B060C4Q34977063-AFBAF7B6-4ADB-4145-8EED-767FF03FFDAFQ34999421-33396E5E-D5FA-42F8-A553-FC2F6B7C12CFQ35088311-9618857A-25AA-42A2-9F4F-13F6D78A1A66Q35287351-E846F758-E0D1-45B0-AFF6-83878E27EC52Q35524335-BCD3CB80-A67B-4521-A491-06386CA3245EQ35683268-B0F2C393-494F-43C3-8235-FE27A3CA3C0CQ35837949-14EAFA13-F5D9-4D0C-AC36-7E0DE761159CQ35872321-55B7EEE0-E7F1-4E99-83F7-DAAE9223081C
P2860
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical implications of the E ...... its ligands in ovarian cancer.
@en
Clinical implications of the ErbB/epidermal growth factor
@nl
type
label
Clinical implications of the E ...... its ligands in ovarian cancer.
@en
Clinical implications of the ErbB/epidermal growth factor
@nl
prefLabel
Clinical implications of the E ...... its ligands in ovarian cancer.
@en
Clinical implications of the ErbB/epidermal growth factor
@nl
P2093
P1476
Clinical implications of the E ...... its ligands in ovarian cancer.
@en
P2093
Andre T Baron
Jacqueline M Lafky
Jason A Wilken
Nita J Maihle
P304
P356
10.1016/J.BBCAN.2008.01.001
P407
P577
2008-02-07T00:00:00Z